Lowers the Total cholesterol (Total-C), LDL-cholesterol (LDL-C), apo B protein (Apo B) and triglyceride (TG) in
patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed hyperlipidemia.
Increase the HDL-cholesterol (HDL-C), administered as an adjuvant to the diet.
Homozygous familial hypercholesterolemia (HoFH)
Adjuvant to other lipid-lowering therapies (ex, LDL Apheresis) to reduce elevated total cholesterol and LDL-cholesterol in Homozygous familial hypercholesterolemia (HoFH) patients, or when other lipid-lowering therapies are not available,
Many risk factors should be considered when administering lipid-modulating drugs to patients with increased risk of atherosclerotic vascular disease due to hypercholesterolemia. Lipid modulating drugs should be used in conjunction with appropriate regimens (including saturated fat and cholesterol restrictions) and inadequate response to diet and other nonpharmacological measures